Lynch & Associates IN Has $1.56 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Lynch & Associates IN increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 8.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,980 shares of the medical research company’s stock after acquiring an additional 386 shares during the period. Lynch & Associates IN’s holdings in Amgen were worth $1,556,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Certuity LLC lifted its stake in Amgen by 72.7% in the second quarter. Certuity LLC now owns 2,249 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 947 shares during the last quarter. Kerusso Capital Management LLC acquired a new stake in Amgen in the 2nd quarter valued at about $3,123,000. Counterweight Ventures LLC grew its holdings in Amgen by 2.9% during the second quarter. Counterweight Ventures LLC now owns 7,330 shares of the medical research company’s stock worth $2,290,000 after purchasing an additional 205 shares during the period. Fiducient Advisors LLC increased its position in Amgen by 5.8% during the second quarter. Fiducient Advisors LLC now owns 5,023 shares of the medical research company’s stock worth $1,570,000 after buying an additional 274 shares during the last quarter. Finally, Asset Dedication LLC lifted its position in shares of Amgen by 9.5% in the second quarter. Asset Dedication LLC now owns 19,091 shares of the medical research company’s stock valued at $5,965,000 after buying an additional 1,654 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ:AMGN opened at $320.56 on Friday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The company has a market cap of $171.96 billion, a price-to-earnings ratio of 45.79, a PEG ratio of 2.96 and a beta of 0.61. The stock has a fifty day moving average price of $326.26 and a 200-day moving average price of $302.25.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same period in the prior year, the company earned $5.00 EPS. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year. As a group, equities analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.81%. Amgen’s dividend payout ratio (DPR) is 128.57%.

Analyst Ratings Changes

A number of research analysts recently weighed in on AMGN shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $305.00 target price (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Morgan Stanley dropped their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 11th. Royal Bank of Canada lifted their target price on shares of Amgen from $332.00 to $362.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. Oppenheimer reissued an “outperform” rating and issued a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. Finally, Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average price target of $327.28.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.